Physician profile
Jodi Belinski
NPI 1295745941
$415.63
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.62 · 2022: $58.75 · 2023: $207 · 2024: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $71.45 | 2023-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $43.78 | 2022 | |
| Xeris Pharmaceuticals, INC. | $42.96 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $38.21 | 2023-2024 | Repatha, Otezla |
| Lilly USA, LLC | $32.84 | 2022-2023 | Mounjaro |
| Abbott Laboratories | $30.08 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $23.34 | 2024 | |
| Novo Nordisk INC | $22.53 | 2023 | Wegovy |
| Phathom Pharmaceuticals, INC. | $21.87 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $21.87 | 2024 | Arexvy, Shingrix |
| Dexcom, INC. | $18.14 | 2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $17.91 | 2023 | Farxiga |
| Vertiflex, INC. | $15.62 | 2019 | |
| Sanofi Pasteur INC. | $15.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Belinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.